Have any of you gentlemen had a bad reaction when stopping abiraterone? I’ve been in the current study for LU-PSMA-617 for the past 14 months; it’s evaluating the effectiveness of Pluvicto given at the beginning of the journey before chemo, but i’ve been in the control group. My last bone scan July 12, 2024 showed progression, so I’ll be crossing over into the active arm of the study in the coming weeks. MO said I could stop taking the abiraterone if I wanted to (although it could hypothetically still be doing some small good) because I would stop the drug when starting Pluvicto. So I stopped the abi.
By day 5 after I was in rough shape: bone and muscle aches everywhere; it was very hard to function. So I started the abiraterone again - and all is good. Anyone else have this experience?
Thank you
Written by
NewGame
To view profiles and participate in discussions please or .
I am in a very similar clinical trial investigating the effectiveness of Lutetium-177 pre-chemotherapy. Like you I was initially placed in the standard-of-care (SOC) control group. The clinical trial doctor wanted me to drop Xtandi (enzalutamide) which I had been taking for five years in favour of Zytiga (abiraterone) plus Prednisone. I was on that for a year. When my PSA started climbing I was allowed to crossover into the Lutetium arm. I have now completed three infusions with the fourth scheduled for the first week of August. When I crossed over to the Lutetium arm I was told by Cancer Agency doctors that I had to slowly wean myself off Prednisone. A pill every second day, half pills, 1/4 pills etc. The slower the process the better. The symptoms you describe might be a result of coming off the Prednisone too quickly. Good luck!
Hello. Thanks for writing. The abi and lupron failed after 12 months, leading to progression of my bone mets and a rise in my PSA to 54. That’s what has led to my crossing over in the study from the control group to the active arm. I don’t think the study is currently seeking participants, but if it’s successful it will hopefully lead to the FDA approving Pluvicto for use at the beginning of treatment pre-chemo. The following article is not an explanation of the study, but of the progress of the study up to this point.
“Novartis finally ready for Pluvicto filing in earlier prostate cancer as patient survival data clear up
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.